Brief: Candel Therapeutics Announces Oral Presentation Of Updated Data From Its Phase 1 Clinical Trial Of CAN-3110

Candel Therapeutics

18/11/2022 13:08

Nov 18 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS ANNOUNCES ORAL PRESENTATION OF UPDATED
DATA
FROM ITS PHASE 1 CLINICAL TRIAL OF CAN-3110 IN 41 PATIENTS WITH
RECURRENT HIGH-GRADE GLIOMA AT THE SOCIETY FOR NEURO-ONCOLOGY
27TH ANNUAL MEETING
    * CANDEL THERAPEUTICS INC - NO DOSE-LIMITING TOXICITIES
OBSERVED
IN 41 PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (RHGG)
    * CANDEL THERAPEUTICS INC - MEDIAN OVERALL SURVIVAL WAS 11.6
MONTHS AFTER A SINGLE INJECTION OF CAN-3110 IN PATIENTS WITH
RHGG

Source text for Eikon:  ID:nGNXgwGN2 
Further company coverage:  CADL.O